Anti-KCNQ1 K+ channel autoantibodies increase IKs current and are associated with QT interval shortening in dilated cardiomyopathy

Cardiovascular Research

Volumn 98, Issue 3, 2013, Pages 496-503

  Li, Jin ^a   Seyler, Claudia ^a   Wiedmann, Felix ^a   Schmidt, Constanze ^a   Schweizer, Patrick A ^a   Becker, Rüdiger ^a   Katus, Hugo A ^a   Thomas, Dierk ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Antibody; Delayed rectifier potassium current; Dilated cardiomyopathy; KCNQ1; Short QT interval

Indexed keywords

AUTOANTIBODY; POTASSIUM CHANNEL KCNE1; POTASSIUM CHANNEL KCNQ1; POTASSIUM CHANNEL KCNQ1 ANTIBODY; UNCLASSIFIED DRUG;

AGED; ANTIBODY SCREENING; ARTICLE; CELL STRAIN HEK293; CELL SURFACE; CONFOCAL MICROSCOPY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE SEVERITY; ELECTROCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HEART REPOLARIZATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN DOMAIN; QT INTERVAL;

ANTIBODY; DELAYED RECTIFIER POTASSIUM CURRENT; DILATED CARDIOMYOPATHY; KCNQ1; SHORT QT INTERVAL;

ACTION POTENTIALS; ADULT; AGED; ARRHYTHMIAS, CARDIAC; AUTOANTIBODIES; CARDIOMYOPATHY, DILATED; ELECTROCARDIOGRAPHY; FEMALE; HEART CONDUCTION SYSTEM; HEK293 CELLS; HUMANS; KCNQ1 POTASSIUM CHANNEL; MALE; MIDDLE AGED; PILOT PROJECTS; TIME FACTORS; TRANSFECTION;

EID: 84877982076     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt046     Document Type: Article

References (39)

1. Yoshikawa T, Baba A, Nagatomo Y. Autoimmune mechanisms underlying dilated car-diomyopathy. Circ J 2009;73:602-607.
2. Lee HC, Huang KT, Wang XL, Shen WK. Autoantibodies and cardiac arrhythmias. Heart Rhythm 2011;8:1788-1795.
3. Fu M. Autoantibodies in atrial fibrillation: actors, biomarkers or bystanders? How far have we come? Cardiology 2009;112:178-179.
4. Fukuda Y, Miyoshi S, Tanimoto K, Oota K, Fujikura K, Iwata M et al. Autoimmunity against the second extracellular loop of beta(1)-adrenergic receptors induces early afterdepolarization and decreases in K-channel density in rabbits. J Am Coll Cardiol 2004;43:1090-1100.
5. Nakamura K, Katayama Y, Kusano KF, Haraoka K, Tani Y, Nagase S et al. Anti-KCNH2 antibody-induced long QT syndrome: novel acquired form of long QT syndrome. J Am Coll Cardiol 2007;50:1808-1809.
6. Thomas D, Kiehn J, Katus HA, Karle CA. Defective protein trafficking in hERG-associated hereditary long QT syndrome (LQT2): molecular mechanisms and restoration of intracellular protein processing. Cardiovasc Res 2003;60:235-241.
7. Thomas D, Karle CA, Kiehn J. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications. Curr Pharm Des 2006;12:2271-2283.
8. Boutjdir M, Chen L, Zhang ZH, Tseng CE, DiDonato F, Rashbaum W et al. Arrhyth-mogenicity of IgG and anti-52-kD SSA/Ro affinity-purified antibodies from mothers of children with congenital heart block. Circ Res 1997;80:354-362.
9. Mazel JA, El-Sherif N, Buyon J, Boutjdir M. Electrocardiographic abnormalities in a murine model injected with IgG from mothers of children with congenital heart block. Circulation 1999;99:1914-1918.
10. Lazzerini PE, Capecchi PL, Acampa M, Selvi E, Guideri F, Bisogno S et al. Arrhythmo-genic effects of anti-Ro/SSA antibodies on the adult heart: more than expected? Autoimmun Rev 2009;9:40-44.
11. Lazzerini PE, Capecchi PL, Laghi-Pasini F. Anti-Ro/SSA antibodies and cardiac arrhythmias in the adult: facts and hypotheses. Scand J Immunol 2010;72:213-222.
12. Irani S, Lang B. Autoantibody-mediated disorders of the central nervous system. Auto-immunity 2008;41:55-65.
13. Wulff H, Castle NA, Pardo LA. Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov 2009;8:982-1001.
14. Mestroni L, Maisch B, McKenna WJ, Schwartz K, Charron P, Rocco C et al. Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyop-athy. Eur Heart J 1999;20:93-102.
15. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-2442.
16. Rautaharju PM, Surawicz B, Gettes L. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram-Part IV: The ST segment, T and U waves, and the QT interval. Circulation 2009;119:e235-e240.
17. Chiladakis J, Kalogeropoulos A, Arvanitis P, Koutsogiannis N, Zagli F, Alexopoulos D. Heart rate-dependence of QTc intervals assessed by different correction methods in patients with normal or prolonged repolarization. Pacing Clin Electrophysiol 2010;33: 553-560.
18. Rautaharju PM, Zhang ZM, Prineas R, Heiss G. Assessment of prolonged QT and JT intervals in ventricular conduction defects. Am J Cardiol 2004;93:1017-1021.
19. Ehlert FA, Goldberger JJ, Rosenthal JE, Kadish AH. Relation between QT and RR intervals during exercise testing in atrial fibrillation. Am J Cardiol 1992;70:332-338.
20. Larroude CE, Jensen BT, Agner E, Toft E, Torp-Pedersen C, Wachtell K et al. Beat-to-beat QT dynamics in paroxysmal atrial fibrillation. Heart Rhythm 2006;3: 660-664.
21. Crow RS, Hannan PJ, Folsom AR. Prognostic significance of corrected QT and corrected JT interval for incident coronary heart disease in a general population sample stratified by presence or absence of wide QRS complex: the ARIC Study with 13 years of follow-up. Circulation 2003;108:1985-1989.
22. Thomas D, Wendt-Nordahl G, Rockl K, Ficker E, Brown AM, Kiehn J. High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872. J Pharmacol Exp Ther 2001;297: 753-761.
23. Bikou O, Thomas D, Trappe K, Lugenbiel P, Kelemen K, Koch M et al. Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model. Cardiovasc Res 2011;92:218-225.
24. Trappe K, Thomas D, Bikou O, Kelemen K, Lugenbiel P, Voss F et al. Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3: a pre-clinical pilot study. Eur Heart J 2013;34:147-157.
25. Lugenbiel P, Bauer A, Kelemen K, Schweizer PA, Becker R, Katus HA et al. Biological heart rate reduction through genetic suppression of Gas protein in the sinoatrial node. J Am Heart Assoc 2012;1:jah3-e000372.
26. Lugenbiel P, Thomas D, Kelemen K, Trappe K, Bikou O, Schweizer PA et al. Genetic suppression of Gas protein provides rate control in atrial fibrillation. Basic Res Cardiol 2012;107:1-12.
27. Soucek R, Thomas D, Kelemen K, Bikou O, Seyler C, Voss F et al. Genetic suppression of atrial fibrillation using a dominant-negative ether-a-go-go-related gene mutant. Heart Rhythm 2012;9:265-272.
28. + current, HERG and KvLQT1/minK potassium channels. Br J Pharmacol 2003;140:996-1002.
29. Chen J, Weber M, Um SY, Walsh CA, Tang Y, McDonald TV. A dual mechanism for I(Ks) current reduction by the pathogenic mutation KCNQ1-S277L. Pacing Clin Elec-trophysiol 2011;34:1652-1664.
30. Ks upregulation in human long-QT syndrome type 1. Circ Res 2012;110:211-219.
31. Patel C, Yan GX, Antzelevitch C. Short QT syndrome: from bench to bedside. Circ Arrhythm Electrophysiol 2010;3:401-408.
32. Xu SZ, Zeng F, Lei M, Li J, Gao B, Xiong C et al. Generation of functional ion-channel tools by E3 targeting. Nat Biotechnol 2005;23:1289-1293.
33. Dallas M, Deuchars SA, Deuchars J. Immunopharmacology: utilizing antibodies as ion channel modulators. Expert Rev Clin Pharmacol 2010;3:281-289.
34. Diamond B, Huerta PT, Mina-Osorio P, Kowal C, Volpe BT. Losing your nerves? Maybe it's the antibodies. Nat Rev Immunol 2009;9:449-456.
35. Naylor J, Beech DJ. Extracellular ion channel inhibitor antibodies. Open Drug Discov J 2009;1:36-42.
36. Kang C, Tian C, Sönnichsen FD, Smith JA, Meiler J, George AL Jr et al. Structure of KCNE1 and implications for how it modulates the KCNQ1 potassium channel. Biochemistry 2008;47:7999-8006.
37. Romey G, Attali B, Chouabe C, Abitbol I, Guillemare E, Barhanin J et al. Molecular mechanism and functional significance of the MinK control of the KvLQT1 channel activity. J Biol Chem 1997;272:13716-16713.
38. Bednar MM, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN. The QT interval. Prog Cardiovasc Dis 2001;43:1-45.
39. Benham CD. Simple recipe for blocking ion channels. Nat Biotechnol 2005;23: 1234-1235.